These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 22386728

  • 1. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
    Kim Y, Gast SM, Endo T, Lu D, Carson D, Schmidt-Wolf IG.
    Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
    [Abstract] [Full Text] [Related]

  • 2. Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid.
    Schmidt M, Kim Y, Gast SM, Endo T, Lu D, Carson D, Schmidt-Wolf IG.
    In Vivo; 2011 May; 25(3):325-33. PubMed ID: 21576405
    [Abstract] [Full Text] [Related]

  • 3. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.
    Kim Y, Schmidt M, Endo T, Lu D, Carson D, Schmidt-Wolf IG.
    In Vivo; 2011 May; 25(6):887-93. PubMed ID: 22021681
    [Abstract] [Full Text] [Related]

  • 4. In vivo efficacy of griseofulvin against multiple myeloma.
    Kim Y, Alpmann P, Blaum-Feder S, Krämer S, Endo T, Lu D, Carson D, Schmidt-Wolf IG.
    Leuk Res; 2011 Aug; 35(8):1070-3. PubMed ID: 21112630
    [Abstract] [Full Text] [Related]

  • 5. Increased in vivo efficacy of lenalidomide by addition of piroctone olamine.
    Kim Y, Alpmann P, Blaum-Feder S, Krämer S, Endo T, Lu D, Carson D, Schmidt-Wolf IG.
    In Vivo; 2011 Aug; 25(1):99-103. PubMed ID: 21282741
    [Abstract] [Full Text] [Related]

  • 6. In vitro efficacy of cinnarizine against lymphoma and multiple myeloma.
    Schmeel LC, Schmeel FC, Kim Y, Blaum-Feder S, Endo T, Schmidt-Wolf IG.
    Anticancer Res; 2015 Feb; 35(2):835-41. PubMed ID: 25667464
    [Abstract] [Full Text] [Related]

  • 7. Targeting the Wnt/beta-catenin pathway in multiple myeloma.
    Schmeel LC, Schmeel FC, Kim Y, Endo T, Lu D, Schmidt-Wolf IG.
    Anticancer Res; 2013 Nov; 33(11):4719-26. PubMed ID: 24222106
    [Abstract] [Full Text] [Related]

  • 8. Targeting Wnt pathway in lymphoma and myeloma cells.
    Schmidt M, Sievers E, Endo T, Lu D, Carson D, Schmidt-Wolf IG.
    Br J Haematol; 2009 Mar; 144(5):796-8. PubMed ID: 19036118
    [No Abstract] [Full Text] [Related]

  • 9. beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model.
    Ashihara E, Kawata E, Nakagawa Y, Shimazaski C, Kuroda J, Taniguchi K, Uchiyama H, Tanaka R, Yokota A, Takeuchi M, Kamitsuji Y, Inaba T, Taniwaki M, Kimura S, Maekawa T.
    Clin Cancer Res; 2009 Apr 15; 15(8):2731-8. PubMed ID: 19351774
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L, Podar K, Chauhan D, Masciari S, Gozzini A, Tagliaferri P, Venuta S, Munshi NC, Anderson KC.
    Clin Cancer Res; 2005 Jun 01; 11(11):4251-8. PubMed ID: 15930364
    [Abstract] [Full Text] [Related]

  • 11. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT, Odeleye A, Huizenga E, Dalton WS, Weinstein RS, Grogan TM.
    Clin Cancer Res; 1995 Dec 01; 1(12):1563-70. PubMed ID: 9815957
    [Abstract] [Full Text] [Related]

  • 12. Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway.
    Schmeel FC, Schmeel LC, Kim Y, Schmidt-Wolf IG.
    Hematol Oncol; 2014 Dec 01; 32(4):197-204. PubMed ID: 24470348
    [Abstract] [Full Text] [Related]

  • 13. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
    Wang YD, Hu Y, Zhang L, Huang J, Sun CY.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct 01; 28(10):659-63. PubMed ID: 18399169
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
    Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD.
    Bone; 2008 Apr 01; 42(4):669-80. PubMed ID: 18294945
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
    van der Spek E, Bloem AC, Lokhorst HM, van Kessel B, Bogers-Boer L, van de Donk NW.
    Leuk Res; 2009 Jan 01; 33(1):100-8. PubMed ID: 18621417
    [Abstract] [Full Text] [Related]

  • 19. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec 01; 17(98):230-2. PubMed ID: 19422142
    [Abstract] [Full Text] [Related]

  • 20. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A, Jagannath S.
    Best Pract Res Clin Haematol; 2006 Dec 01; 19(4):769-80. PubMed ID: 16997182
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.